A docetaxel-based PNP formulation
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Docetaxel Polymeric Nanoparticles

Item No. 39769

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Docetaxel PNPs
  • Docetaxel Polymer-based Nanoparticles
  • DTX PNPs
  • RP 56976 PNPs
Formulation (Request formulation change)
2 mg of docetaxel contained in TBS-buffered TPGS and poloxanlene polymeric nanoparticles containing trehalose
Storage Buffer
TBS, pH 7.4, when resuspended in 1 ml water
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    2 mg

    $769

    Add
    Cayman Chemical
    Visit Our Lipid Nanoparticle Resource Center for Additional Tools & Resources
    EXPLORE NOW
    Product Description

    Docetaxel polymeric nanoparticles (PNPs) are nanoparticles composed of tocofersolan (TPGS; Item No. 34661), poloxanlene, trehalose (Item No. 20517), and TBS that encapsulate docetaxel (Item No. 11637) and are 15 to 20 nm in size as determined by dynamic light scattering (DLS). PNP formulations are a lipid-based drug delivery (LBDD) system that improve drug bioavailability and solubility, protect the cargo from degradation or metabolism, control drug release, and help lower the biological impacts observed by DMSO and other organic solvents.1,2 Docetaxel is a microtubule-stabilizing agent and a semisynthetic derivative of paclitaxel (Item No. 10461).3 Formulations containing docetaxel have been used in the treatment of head and neck, breast, and non-small cell lung cancer, gastric adenocarcinoma, and castration-resistant prostate cancer.

    Before use, reconstitute the docetaxel PNPs in 1 ml of deionized water and dilute the reconstituted docetaxel PNPs prior to performing biological experiments.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Zielińska, A., Carreiró, F., Oliveira, A.M., et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules 25(16), 3731 (2020).

    2. Begines, B., Ortiz, T., Pérez-Aranda, M., et al. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials (Basel) 10(7), 1403 (2020).

    3. Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51(18), 4845-4852 (1991).